Combination Sitagliptin, Tacrolimus, Sirolimus for Prophylaxis of Acute Graft-vs-Host-Disease
Investigators aimed to determine whether DPP-4 inhibition reduces the incidence of acute graft-vs-host disease among patients receiving allogeneic HSCT.
Investigators aimed to determine whether DPP-4 inhibition reduces the incidence of acute graft-vs-host disease among patients receiving allogeneic HSCT.
A sequenced reduced-intensity conditioning regimen may not improve outcomes for patients with acute myeloblastic leukemia and myelodysplasia after allogeneic stem cell transplantation.
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
Treatment of symptomatic chronic subdural hematoma with dexamethasone may worsen outcomes compared with placebo.
For patients with acute myeloid leukemia, a total of 4 courses of chemotherapy may improve relapse rates but not overall survival, compared with 3 total courses of treatment.
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
Company also looking to widen eligibility for the vaccine to include pregnant women, children, and others.
A recently published review outlines the approach to the treatment of venous thromboembolism in pregnancy using patient case studies from their clinical practice in a Netherlands-based academic hospital.
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
Please login or register first to view this content.